{"paper_id": "a87913336d15af51143dda9b56b9cebe5a95a871", "metadata": {"title": "Journal Pre-proof Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Risk factors for severity and mortality in adult COVID-19 1 inpatients in Wuhan", "authors": [{"first": "Xiaochen", "middle": [], "last": "Li", "suffix": "", "affiliation": {"laboratory": "", "institution": "United Imaging Healthcare Co", "location": {"settlement": "Ltd, Wuhan", "country": "China"}}, "email": ""}, {"first": "Shuyun", "middle": [], "last": "Xu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Muqing", "middle": [], "last": "Yu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Ke", "middle": [], "last": "Wang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yu", "middle": [], "last": "Tao", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University of Science and Technology", "location": {"settlement": "Wuhan", "country": "China"}}, "email": ""}, {"first": "Ying", "middle": [], "last": "Zhou", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jing", "middle": [], "last": "Shi", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Min", "middle": [], "last": "Zhou", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Bo", "middle": [], "last": "Wu", "suffix": "", "affiliation": {"laboratory": "", "institution": "United Imaging Healthcare Co", "location": {"settlement": "Ltd, Wuhan", "country": "China"}}, "email": ""}, {"first": "Zhenyu", "middle": [], "last": "Yang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Cong", "middle": [], "last": "Zhang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Junqing", "middle": [], "last": "Yue", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhiguo", "middle": [], "last": "Zhang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Harald", "middle": [], "last": "Renz", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Xiansheng", "middle": [], "last": "Liu", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Jungang", "middle": [], "last": "Xie", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Min", "middle": [], "last": "Xie", "suffix": "", "affiliation": {}, "email": "xie_m@126.com"}, {"first": "Jianping", "middle": [], "last": "Zhao", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Li", "middle": ["X"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Xu", "middle": ["S"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yu", "middle": ["M"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Wang", "middle": ["K"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Tao", "middle": ["Y"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhou", "middle": ["Y"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Shi", "middle": ["J"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhou", "middle": ["M"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Wu", "middle": ["B"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yang", "middle": ["Z"], "last": "Zhang", "suffix": "", "affiliation": {}, "email": ""}, {"first": "C", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yue", "middle": ["J"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhang", "middle": ["Z"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Renz", "middle": ["H"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Liu", "middle": ["X"], "last": "Xie", "suffix": "", "affiliation": {}, "email": ""}, {"first": "J", "middle": [], "last": "Xie", "suffix": "", "affiliation": {"laboratory": "Key Laboratory of Respiratory Diseases", "institution": "National Ministry of Health of the People's Republic", "location": {}}, "email": ""}, {"first": "M", "middle": [], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhao", "middle": ["J"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": "M", "middle": ["D"], "last": "", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "Muqing", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Yu", "middle": [], "last": "Md", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "Ke", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Wang", "middle": [], "last": "Md", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "Cong", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhang", "middle": [], "last": "Md", "suffix": "", "affiliation": {}, "email": ""}, {"first": ";", "middle": [], "last": "Zhiguo", "suffix": "", "affiliation": {}, "email": ""}, {"first": "Zhang", "middle": [], "last": "Phd", "suffix": "", "affiliation": {"laboratory": "", "institution": "Huazhong University of Science and Technology", "location": {"settlement": "Wuhan", "country": "China"}}, "email": ""}, {"first": ";", "middle": ["Xiansheng"], "last": "Liu", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "word count: 234 36 37 Author Contributions: JZ, MX, SX and MZ conceived and designed the study. XLi and MX 38 contributed to the literature search and writing of the report. MY, KW, YT, YZ and JS contributed 39 to data collection. HR, XLi, BW, MX, ZY, CZ, JY and ZZ contributed to data analysis and data 40 interpretation. HR, XLiu and JX contributed to revision of the manuscript. 41 42", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "The SARS-CoV-2 virus, as a betacoronavirus, shares 88% of two bat-derived SARS-like 133 coronaviruses and distances from SARS-CoV (around 79%) and Middle East respiratory 134 syndrome coronavirus (MERS-CoV, around 50%). 1 SARS and MERS epidemics posed threats to 135 global health due to high mortality rates of 9.6% for SARS-CoV and 34.4% for MERS-CoV 136 globally. 2, 3 Epidemiological data released by the Chinese Center for Disease Control and 137 Prevention showed that 50,005 confirmed cases have been identified in Wuhan and 31,513 in 138 mainland China except Wuhan as of March 22, 2020. The mortality rate of COVID-19 patients 139 was 5.0% in Wuhan, which was close to that in the world (4.2%) and much higher than that in 140 mainland China except Wuhan (2.4%). This study aims to describe and compare the 141 epidemiological, demographic, clinical, laboratory and radiological characteristics as well as the 142 complications, treatment and outcomes of hospitalized patients with nonsevere and severe 143 COVID-19. Potential risk factors for severe COVID-19 and factors associated with death in severe 144 cases were analyzed to provide scientific data for relieve severe cases and reduce mortality. 145", "cite_spans": [{"start": 436, "end": 451, "text": "Control and 137", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "This study was an ambispective cohort study of consecutive hospitalized patients with COVID-19 159 enrolled at Sino-French New City Branch of Tongji Hospital, Huazhong University of Science and 160", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "Technology in Wuhan from January 26, 2020 to February 5, 2020. The final date of follow-up was 161", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "March 3, 2020. Sino-French New City Branch of Tongji hospital is one of the major nationally 162 designated hospitals only providing medical care for adult COVID-19 patients in Wuhan. All 163 cases with COVID-19 enrolled in this study were diagnosed based on the WHO interim guidance 4 164 and the diagnostic and treatment guideline for COVID-19 issued by Chinese National Health 165", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "Committee (version 5). Detection of SARS-CoV-2 nucleic acids was shown in text in the Online 166", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "Repository. 5 This study was approved by Institutional Review Board of Tongji Hospital, 167", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "Huazhong University of Science and Technology. Written informed consent was waived in light 168 of the urgent need to collect data. 169", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "The epidemiological and demographic data were obtained by face-to-face or telephone interview. 170", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "Clinical symptoms, laboratory, and radiological findings on admission as well as the 171 complications, treatment and outcomes during hospitalization were extracted from electronic 172 medical records. Serum cytokines (IL-1\u03b2, IL-2R, IL-6, IL-8, IL-10 and TNF-\u03b1) were measured on 173 admission. Patient data were cross-checked for consistency before final data entry and then 174 entered into a computerized database. 175", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "The presence of underlying comorbidities was identified based on the International Classification 176 of Diseases and Injuries-10 diagnostic codes. The complications of COVID-19 after admission 177", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "were assessed and the definitions were shown in text in the Online Repository. Cardiac injury was 178 one of the complications, which was defined as a serum hypersensitive cardiac troponin I level 179 higher than 15.6 pg/ml without acute coronary symptoms or abnormal electrocardiogram. The 180 clinical outcomes were classified into discharge from hospital, in-hospitalization, and death. 181", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "Severe COVID-19 was defined according to 2019 clinical practice guideline from Infectious 182 Diseases Society of America and American Thoracic Society for diagnosis and treatment of adults 183 with community-acquired pneumonia. 6 Based on whether or not requiring ventilatory support on admission, severe cases upon admission were divided into two cohorts, severely ill and critically ill cases. 186", "cite_spans": [], "ref_spans": [], "section": "Data source 158"}, {"text": "The descriptive statistics are median and interquartile range (IQR) for continuous data. ", "cite_spans": [], "ref_spans": [], "section": "Statistical analysis 187"}, {"text": "A total of 549 patients with COVID-19 were enrolled, of whom 548 cases were included in the 219 study. One case not meeting inclusion criteria was excluded due to inclusion criteria. Almost half 220 of the patients (49.1%, 269 of 548) were identified as severe cases and 50.9% (279 of 548) were 221 nonsevere cases on admission. 68.7% (347 of 505) of cases were positive for SARS-CoV-2 222 nucleic acid test pre-admission. Comparison of findings between nonsevere and severe cases in 223 the patients with positive viral nucleic acid test pre-admission showed essentially the similar 224 differences to that in the total patients (see Table E1 in the Online Repository). 225", "cite_spans": [], "ref_spans": [{"start": 635, "end": 643, "text": "Table E1", "ref_id": null}], "section": "Epidemiological and demographic characteristics 218"}, {"text": "The epidemiological and demographic characteristics are shown in Table 1 . 52 (9.5%) of 546 226 patients got the infection in hospital. 45 (8.2%) of 547 patients were health-care workers and 67 227 (12.2%) patients were family members of health-care workers. Nonsevere cases had a higher 228", "cite_spans": [], "ref_spans": [{"start": 65, "end": 72, "text": "Table 1", "ref_id": null}], "section": "Epidemiological and demographic characteristics 218"}, {"text": "proportion of health-care workers and family members than severe cases (P<0.001). The date of 229 onset of the first reported case with COVID-19 was December 1, 2019. 7 The median time from 230", "cite_spans": [], "ref_spans": [], "section": "Epidemiological and demographic characteristics 218"}, {"text": "December 1, 2019 to the onset of COVID-19 was 54 days, ranging from 19 days to 63 days. 231", "cite_spans": [], "ref_spans": [], "section": "Epidemiological and demographic characteristics 218"}, {"text": "The median age of study population was 60 years (IQR 48-69), ranging from 18 years to 95 years, 232 of whom 210 (38.3%) were aged 65 years or older. The patients aged 65 years or older in severe 233 cases were almost twice as nonsevere cases of the same age (50.2% vs. 26.9%, P<0.001). Slightly 234 more than half (50.9%) of all patients were male and the proportion of males in severe cases is 235 higher than in nonsevere cases (56.9% vs. 45.2%, P=0.006). 236", "cite_spans": [], "ref_spans": [], "section": "Epidemiological and demographic characteristics 218"}, {"text": "19.2% of patients with severe COVID-19 were smokers (Table 1) asthma (0.9%) were identified in total population. 42 (7.7%) of 545 patients regularly took 242 angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers; no significant 243 difference was found between nonsevere and severe cases. sore throat (5.1%), cough (75.5%), chest pain (7.5%), dyspnea (56.6%), chest tightness (38.1%), 246 dizziness (10.2%), confusion (3.1%), headache (11.3%), myalgia (20.3%), vomiting (8.2%), 247 diarrhea (32.7%), abdominal pain (2.9%). 6 patients were asymptomatic and diagnosed by CT 248 screening. Duration of fever pre-admission was significantly longer among severe cases compared 249 with that in nonsevere cases (P=0.031). Severe cases experienced longer duration from onset to 250 outpatient visit and longer duration from onset to hospitalization compared with nonsevere cases 251 (p=0.018 and p=0.035, respectively). 64 (11.9%) of 540 patients were treated with corticosteroids 252 delivered by oral or intravenous pre-admission. 304 (56.5%) of 538 patients had received at least 253 one of the following antiviral medications: umifenovir (32.9%), oseltamivir (35.1%), 254 lopinavir/ritonavir (2.4%), and ribavirin (1.5%). 255", "cite_spans": [], "ref_spans": [{"start": 52, "end": 61, "text": "(Table 1)", "ref_id": null}], "section": "Clinical characteristics on admission 237"}, {"text": "CT scans for 461 patients were evaluated pre-admission, and showed multilobar pulmonary 257 infiltrates in 436 patients ( Table 2 ). The median time from onset to pneumonia diagnosed by CT 258 scan was 4 days. On admission, oxygen saturation (SpO2) less than 93.1% on room air presented 259 in 33.3% of all patients, of whom 163 (89%) were severe cases. 90.2% of all patients experienced 260 lymphopenia (<1500 cells per mm 3 ) and 29.1% of all patients had thrombocytopenia (<150,000 261 cells per mm 3 ). Compared with nonsevere cases, inflammation-related marker levels (hsCRP, ESR, 262 and ferritin) were significantly higher in severe cases The levels of procalcitonin, globulin, lactate 263 dehydrogenase (LDH), NT-proB-type natriuretic peptide (NT-proBNP), d-dimer, alanine 264 aminotransferase, aspartate aminotransferase, total bilirubin, conjugated bilirubin, blood urea 265 nitrogen, and creatinine were elevated in 9.5%, 40.4%, 73.6%, 27.5%, 67.4%, 23.1%, 33.1%, 266 4.4%, 9.2%, 15.8%, and 27.1% of all patients, respectively. Serum cytokine levels of IL-2R, IL-6, 267 IL-10, and TNF-\u03b1 were significantly higher in severe patients than those in nonsevere patients (all", "cite_spans": [], "ref_spans": [{"start": 122, "end": 129, "text": "Table 2", "ref_id": null}], "section": "Radiographic and laboratory findings on admission 256"}, {"text": "Of the 269 severe cases, 46 were classified as critically ill for requiring respiratory support. 271", "cite_spans": [], "ref_spans": [], "section": "Subgroup analysis 270"}, {"text": "Compared with severely ill cases, the time from December 1, 2019 to onset was shorter and the 272 time from onset to outpatient visit was longer in critically ill cases (see Table E2 in the Online high procalcitonin, high NT-proBNP, high LDH, high d-dimer, low albumin, and high creatinine) 276", "cite_spans": [], "ref_spans": [{"start": 174, "end": 182, "text": "Table E2", "ref_id": null}], "section": "Subgroup analysis 270"}, {"text": "were observed in critically ill cases compared with severely ill cases (all P<0.05). 34.1% of 277 critically ill patients received systemic corticosteroids pre-admission, the proportion of whom was 278 significantly higher than that in severely ill cases (12.2%, P<0.001). 279", "cite_spans": [], "ref_spans": [], "section": "Subgroup analysis 270"}, {"text": "Compared with nonsevere cases, systemic corticosteroid use pre-admission was more common in 280 severe cases with larger cumulative dose and longer duration (P=0.007; P<0.001; P<0.001; 281 respectively). Stratification of patients by corticosteroid exposure is presented in Table E3 in the 282", "cite_spans": [], "ref_spans": [{"start": 274, "end": 282, "text": "Table E3", "ref_id": "TABREF2"}], "section": "Subgroup analysis 270"}, {"text": "Online Repository. Severe patients treated with corticosteroids had higher LDH level compared 283 with severe patients without corticosteroid use pre-admission (P<0.05). 284", "cite_spans": [], "ref_spans": [], "section": "Subgroup analysis 270"}, {"text": "Nonsevere cases were more likely to receive antiviral drugs pre-admission, including umifenovir 285 and oseltamivir (P<0.001 and P=0.005; respectively). In severe case subgroup, the patients 286 receiving umifenovir were younger than those without umifenovir use (P<0.05). A comparison of 287 baseline demographic and clinical characteristics between patients with and without antiviral drug 288 use revealed no marked difference in SpO2 or laboratory findings in both nonsevere and severe 289 case subgroups (see Table E4 and E5 in the Online Repository). 290", "cite_spans": [], "ref_spans": [{"start": 514, "end": 522, "text": "Table E4", "ref_id": null}], "section": "Subgroup analysis 270"}, {"text": "In the final logistic regression model, variables such as age 65 or older (OR 2.2; 95% CI 1.5-3.5), 292 hypertension (OR 2.0; 95% CI 1.3-3.2), LDH >445 U/L (OR 4.4; 95% CI 2.6-7.6), and 293 d-dimer >1 mg/L (OR 2.2; 95% CI 1.4-3.3) were significantly associated with severe cases with 294 COVID-19 ( Figure 1) . 295", "cite_spans": [], "ref_spans": [{"start": 299, "end": 308, "text": "Figure 1)", "ref_id": null}], "section": "Risk factors for severe cases on admission 291"}, {"text": "In the follow-up period, the complications of COVID-19 were assessed , including acute 297 respiratory distress syndrome (ARDS) (38.3%), cardiac injury (21.7%), liver dysfunction (19.3%), 298 acute kidney injury (17.3%), bacteremia (7.7%), diffuse intravascular coagulation (7.7%), and 299 hyperglycemia (33.2%) ( This study provided a comprehensive data on the epidemiological, demographic, clinical, 338 laboratory, and radiological characteristics as well as the complications, treatment, and outcomes 339 of hospitalized patients with nonsevere and severe COVID-19 in Wuhan. Almost half of the 340 patients in this study were identified as severe cases, which may differ from the results of the 341 previous studies. 8 The proportion of patients aged 65 years or older were higher in our study than 342", "cite_spans": [], "ref_spans": [], "section": "Complications, treatment and clinical outcomes during hospitalization and follow-up 296"}, {"text": "in Nanshan Zhong's study (38.8% vs. 15.1%, respectively). 9 The time from December 1, 2019 to 343 the onset of most patients was longer than 50 days. During mid-January to early February, Wuhan 344 experienced the highest peak of COVID-19 outbreak, with a family cluster and high prevalence of 345 COVID-19 in older adults. Longer wait for access to medical care was observed in severe cases 346 compared with that in nonsevere cases. More than half of the patients experienced at least two 347 hospital visits, which may increase the risk of nosocomial transmission events. Diagnosis and 348 treatment may be delayed due to the long wait for access to medical care. Severe COVID-19 349 patients would likely develop ARDS and died of respiratory failure. Although there are currently 350 no effective antiviral drugs for SARS-CoV-2, prompt identification and early respiratory support 351 would relieve severe cases and reduce mortality. The severity of disease in patients with initial 352 positive nucleic acid test was similar to that of all COVID-19 patients. We thus propose that 353 urgent timely diagnosis is crucial, and that early intervention should not be delayed based on 354 nucleic acid test. proinflammatory cytokine levels (INF-\u03b3, IL-1\u03b2, IL-6, IL-8, IL-12, and TNF-\u03b1) and were 362 associated with the development of ARDS. 11-13 In our study, severe COVID-19 patients had (0.9%) in our study was markedly lower than that reported in the adult population of Wuhan 366 (6.4%). 14- 16 We thus speculate that Th2 immune response in asthmatic patients may counter the 367 inflammation process induced by SARS-CoV-2 infection. Further studies are required to 368 characterize the immune response and inflammation features of The majority of severe patients showed rapid progression and multiple organ dysfunction. The to onset in critically ill cases than that in severely ill cases may reflect a higher virulence of 378 SARS-Cov-2, or earlier onset of The risk factors for severity identified in this study included age, high LDH level, and high 380 d-dimer level, consistent with those in previous reports. 15, 20 However, different from the findings 381 of previous studies 21 , hypertension was the only comorbidity associated with the severity of 382 COVID-19 after adjustment for age, sex and smoking status. The distinct features of pneumonia 383 and high severity in patients with COVID-19 in this study may lead to this difference from 384 previous reports. ACE2, a gateway to SARS, was reported to be a protective factor against 385 SARS-CoV-induced lung injury. 22, 23 The association between ACE2 expression and hypertension 386 was confirmed in a previous study. 24 This fact may partly explain the high prevalence of severe 387 COVID-19 in patients with hypertension. LDH has been recognized as a marker for severe 388 prognosis in various diseases, including cancer and infection. 25 The high LDH level in COVID-19 389 in severe cases suggested that LDH may be associated with lung injury and tissue damage, 390", "cite_spans": [{"start": 1494, "end": 1496, "text": "16", "ref_id": null}, {"start": 2582, "end": 2585, "text": "22,", "ref_id": null}, {"start": 2586, "end": 2588, "text": "23", "ref_id": null}, {"start": 2905, "end": 2907, "text": "25", "ref_id": null}], "ref_spans": [], "section": "Complications, treatment and clinical outcomes during hospitalization and follow-up 296"}, {"text": "warranting an investigation for the potential mechanism. 391", "cite_spans": [], "ref_spans": [], "section": "Complications, treatment and clinical outcomes during hospitalization and follow-up 296"}, {"text": "This study evaluated pre-admission medications for patients with severe COVID-19. Although the 392 proportion of nonsevere cases in patients receiving oseltamivir was higher than that in patients 393 without oseltamivir use, stratification analysis showed that there was no significant difference in case subgroup. Therefore, oseltamivir use may just be an indicator of disease severity. The 396 patients receiving umifenovir were younger than those without umifenovir use, indicating that 397 younger patients may have easier access to drugs or prefer umifenovir. 398", "cite_spans": [], "ref_spans": [], "section": "Complications, treatment and clinical outcomes during hospitalization and follow-up 296"}, {"text": "Older age, leukocytosis and high LDH level were reported to be risk factors associated with 399 in-hospital death in previous studies. 20, 26, 27 The present study also revealed that hyperglycemia 400 was related with increased mortality in COVID-19 patients. The prevalence of hyperglycemia may 401 be associated with underlying diabetes and corticosteroid therapy. However, the localization of 402 ACE2 expression in the pancreas in SARS was reported to damage islets, resulting in 403 hyperglycemia 19 ; this finding suggested that hyperglycemia may also be an indicator of severe 404", "cite_spans": [{"start": 135, "end": 138, "text": "20,", "ref_id": null}, {"start": 139, "end": 142, "text": "26,", "ref_id": null}, {"start": 143, "end": 145, "text": "27", "ref_id": null}], "ref_spans": [], "section": "Complications, treatment and clinical outcomes during hospitalization and follow-up 296"}, {"text": "This study indicated that corticosteroid use was more common in severe cases than in nonsevere 406 cases and that high-dose corticosteroid use was related to high risk of death in severe COVID-19 407 patients. High-dose steroid use may be an indicator of disease severity rather than a predisposing 408 factor. In a previous study, treatment with methylprednisolone was shown to be beneficial for 409 COVID-19 patients who developed ARDS. 20 However, critically ill cases had more signs of 410 infection and abnormal laboratory findings, including high leukocyte, high procalcitonin, high 411 d-dimer, low albumin, and high creatinine levels. High-dose corticosteroid use should be used 412 with cautious in critically ill patients to avoid aggravating complications. 413 A recent study by Bin Cao et al showed that lopinavir/ritonavir treatment offered no significant 414 benefit over the standard care for hospitalized adult COVID-19 patients. 28 Cao's study also 415 reported that lopinavir/ritonavir led to a shorter median time to clinical improvement than the 416 standard care (HR 1.39; 95% CI 1.00 to 1.91) in a modified intention-to-treat analysis. Compared 417 with Cao's study, the severity of patients was more serious and lopinavir/ritonavir treatment was 418 associated with a lower risk of death in severe COVID-19 patients in this study. However, our 419 study was an observational study; thus, the benefit of lopinavir/ritonavir for severe COVID-19 420 patients needs to be further confirmed. 421", "cite_spans": [], "ref_spans": [], "section": "COVID-19. 405"}, {"text": "There were limitations to the current study. Firstly, epidemiological data were collected 422 respectively and recall bias might have occurred. Secondly, missing data on some variables, such 423 as detailed information of CT scan, may cause bias in the estimation and reduce the representativeness of the samples. Thirdly, laboratory findings were measured upon admission and may indicate the severity of COVID-19. The causal relationship between abnormal laboratory 426 findings and severity could not be determined. Fourthly, this study was an observational study 427 with limitations in terms of evaluating the efficacy of corticosteroids and antiviral drugs. Finally, 428 the absence of comparative data from COVID-19 patients not admitted or from other critically ill 429 patients were limitations of this study. 430", "cite_spans": [], "ref_spans": [], "section": "COVID-19. 405"}, {"text": "In conclusion, COVID-19 outbreak caused widespread concern and has threatened the global ", "cite_spans": [], "ref_spans": [], "section": "COVID-19. 405"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Clinical characteristics 523 of 140 patients infected with SARS-CoV-2 in Wuhan", "authors": [{"first": "J", "middle": ["J"], "last": "Zhang", "suffix": ""}, {"first": "X", "middle": [], "last": "Dong", "suffix": ""}, {"first": "Y", "middle": ["Y"], "last": "Cao", "suffix": ""}, {"first": "Y", "middle": ["D"], "last": "Yuan", "suffix": ""}, {"first": "Y", "middle": ["B"], "last": "Yang", "suffix": ""}, {"first": "Y", "middle": ["Q"], "last": "Yan", "suffix": ""}], "year": 2020, "venue": "China. Allergy", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "An increased 525 prevalence of self-reported allergic rhinitis in major Chinese cities from", "authors": [{"first": "X", "middle": ["D"], "last": "Wang", "suffix": ""}, {"first": "M", "middle": [], "last": "Zheng", "suffix": ""}, {"first": "H", "middle": ["F"], "last": "Lou", "suffix": ""}, {"first": "C", "middle": ["S"], "last": "Wang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhang", "suffix": ""}, {"first": "M", "middle": ["Y"], "last": "Bo", "suffix": ""}], "year": 2005, "venue": "Allergy", "volume": "71", "issn": "", "pages": "1170--80", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "ACE2 528 links amino acid malnutrition to microbial ecology and intestinal inflammation", "authors": [{"first": "T", "middle": [], "last": "Hashimoto", "suffix": ""}, {"first": "T", "middle": [], "last": "Perlot", "suffix": ""}, {"first": "A", "middle": [], "last": "Rehman", "suffix": ""}, {"first": "J", "middle": [], "last": "Trichereau", "suffix": ""}, {"first": "H", "middle": [], "last": "Ishiguro", "suffix": ""}, {"first": "M", "middle": [], "last": "Paolino", "suffix": ""}], "year": 2012, "venue": "Nature", "volume": "529", "issn": "", "pages": "477--81", "other_ids": {}}, "BIBREF4": {"ref_id": "b4", "title": "Cholangiocytes May Cause Liver Damage After 2019-nCoV Infection", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Binding of SARS coronavirus to its receptor damages 534 islets and causes acute diabetes", "authors": [{"first": "J", "middle": ["K"], "last": "Yang", "suffix": ""}, {"first": "S", "middle": ["S"], "last": "Lin", "suffix": ""}, {"first": "X", "middle": ["J"], "last": "Ji", "suffix": ""}, {"first": "L", "middle": ["M"], "last": "Guo", "suffix": ""}], "year": 2010, "venue": "Acta Diabetol", "volume": "47", "issn": "", "pages": "193--202", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Risk Factors Associated With Acute 536 Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease", "authors": [{"first": "C", "middle": [], "last": "Wu", "suffix": ""}, {"first": "X", "middle": [], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": [], "last": "Cai", "suffix": ""}, {"first": "Xia", "middle": [], "last": "Ja", "suffix": ""}, {"first": "X", "middle": [], "last": "Zhou", "suffix": ""}, {"first": "S", "middle": [], "last": "Xu", "suffix": ""}], "year": 2019, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Comorbidity and its 539 impact on 1590 patients with Covid-19 in China: A Nationwide Analysis", "authors": [{"first": "W", "middle": ["J"], "last": "Guan", "suffix": ""}, {"first": "W", "middle": ["H"], "last": "Liang", "suffix": ""}, {"first": "Y", "middle": [], "last": "Zhao", "suffix": ""}, {"first": "H", "middle": ["R"], "last": "Liang", "suffix": ""}, {"first": "Z", "middle": ["S"], "last": "Chen", "suffix": ""}, {"first": "Y", "middle": ["M"], "last": "Li", "suffix": ""}], "year": null, "venue": "Eur Respir J", "volume": "540", "issn": "", "pages": "", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "where N is the total number of patients with 638 available data. P values comparing nonsevere cases and severe cases are from \u03c7\u00b2 test, Fisher's exact test, 639 or Mann-Whitney U test", "authors": [], "year": null, "venue": "Data are expressed as median (IQR), n (%), or n/N (%)", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "CoV-2 nucleic acid test was performed pre-admission", "authors": [{"first": "*", "middle": [], "last": "Sars-", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Table 3. Complications and treatment during hospitalization and clinical outcomes of COVID-19", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Data are expressed as median (IQR), n (%), or n/N (%), where N is the total number of patients with 676 available data. P values comparing nonsevere cases and severe cases are from \u03c7\u00b2 test, Fisher's exact test", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "ARDS=acute respiratory distress syndrome", "authors": [{"first": "U", "middle": [], "last": "Or Mann-Whitney", "suffix": ""}, {"first": "", "middle": [], "last": "Test", "suffix": ""}], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "2019, an outbreak caused by coronavirus disease 2019 (COVID-19) occurred in 128 Wuhan, Hubei Province, China. As of March 22, 306,506 of COVID-19 cases were reported in 129 over a hundred countries worldwide. More than 12 thousand patients died from infection of this 130 new virus (named severe acute respiratory syndrome coronavirus 2, SARS-CoV-2), urging early 131 identification and intervention for severe cases.132", "latex": null, "type": "figure"}, "FIGREF1": {"text": "during hospitalization were significant risk factors associated with death in severe 319 COVID-19 cases. Lopinavir/ritonavir (adjusted HR 0.4; 95% CI 0.2-0.9) and umifenovir (adjusted 320 HR 0.5; 95% CI 0.3-0.8) were associated with lower death in severe COVID-19 patients. The 321adjusted Kaplan-Meier estimates of survival for sex, age, sex, leukocyte, LDH, corticosteroid use, 322 lopinavir/ritonavir use, and umifenovir use were shown inFigure E1-7 in the Online Repository.", "latex": null, "type": "figure"}, "FIGREF2": {"text": "355There are six coronavirus species currently known to cause human infection. SARS-CoV-2 was 356 most closely related to SARS-CoV through phylogenetic analysis and was revealed to share a 357 similar receptor, ACE-2, to SARS-CoV. 1 This fact hints that COVID-19 may partly mimic SARS 358 infection. The autopsy results of SARS patients showed that high levels of proinflammatory 359 cytokines were expressed in ACE-2-expressing cells infected by SARS-CoV. 10 Plasma cytokine 360 profiles of SARS patients showed Th1-dominated responses with markedly elevated 361", "latex": null, "type": "figure"}, "FIGREF3": {"text": "370 median time from onset to pneumonia diagnosed by CT scan was only 4 days. Approximately one 371 third of the patients experienced gastrointestinal symptoms. During hospitalization, a substantial 372 proportion of patients presented cardiac injury, liver and kidney dysfunction, and hyperglycemia. 373 It was proved that the fecal and urine samples and rectal swabs of COVID-19 patients were 374 positive for SARS-CoV-2 nucleic acids. 9 ACE-2 was reported to be expressed in small intestinal 375 epithelial cells, cholangiocytes, and the pancreas, 17-19 indicating that SARS-CoV-2 infection may 376 induce the multi-organ injury in COVID-19 patients. The shorter duration from December 1, 2019 377", "latex": null, "type": "figure"}, "FIGREF4": {"text": "431 public health security. Recent evidence of possible fecal-oral transmission in SARS-Cov-2 432 infection, asymptomatic infection, 8, 29, 30 and positive result for SARS-Cov-2 test in recovered 433 patients, 31 warrant aggressive measures to suppress and prevent epidemic spreading, such as 434 hygiene maintenance, early screening and intervention, and self-isolation after recovery. As a 435 major transportation hub of China, Wuhan faced increased difficulties in outbreak control. Efforts 436to control COVID-19 need to take into account globalization processes. 32 Severe male patients 437 with heart injury, hyperglycemia, and high-dose corticosteroid use may have high risk of death. and sincerely thank all front-line medical staff for hard work and sacrifice.", "latex": null, "type": "figure"}, "FIGREF5": {"text": "Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of 556 critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, 557 retrospective, observational study. Lancet Respir Med 2020.558 28. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in 559 Adults Hospitalized with Severe Covid-19. N Engl J Med 2020.", "latex": null, "type": "figure"}, "FIGREF6": {"text": "JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of 561 pneumonia associated with the 2019 novel coronavirus indicating person-to-person 562 transmission: a study of a family cluster. Lancet 2020; 395:514-23.", "latex": null, "type": "figure"}, "FIGREF7": {"text": "NC, Shrestha N, Rahman MS, Zaki R, Tan Z, Bibi S, et al. The SARS, MERS 569 and novel coronavirus (COVID-19) epidemics, the newest and biggest global health 570 threats: what lessons have we learned? Int J Epidemiol 2020.", "latex": null, "type": "figure"}, "FIGREF8": {"text": "The effect of various potential risk factors on patients with severe COVID-19 at 577 admission.", "latex": null, "type": "figure"}, "TABREF0": {"text": "The 188 statistics for categorical variables are counts and percentages. Mann-Whitney U test were 189 performed for continuous variables and the \u03c7\u00b2 test and Fisher's exact test were employed for 190 categorical variables as appropriate. Kruskal-Wallis test with the Dunn's multiple comparison 191 were used to compare across groups. 192 Multivariable binary logistic regression analyses were used to assess the association between age, 193 sex, source of infection, underlying comorbidity, number of hospital visit, time from onset to 194 hospitalization, days of fever pre-admission, abnormal laboratory findings and the dependent 195 variable of severity of disease. The odds ratio (OR) along with the 95% confidence interval (95% 196 CI) were reported. Univariable and multivariable analyses to identify factors associated with death 197 from COVID-19 in severe patients were performed by Cox proportional hazards regression model. 198Considering the total number of deaths (n=87) in our study, nine variables were chosen for 199 multivariate Cox model based on the univariable analysis (p<0.05), previous findings and clinical 200 importance, including sex, age, laboratory findings (blood leukocyte count and lactose 201 dehydrogenase) on admission, the complications (cardiac injury and hyperglycemia) and drug 202 therapy (corticosteroid, lopinavir/ritonavir, and umifenovir) during hospitalization. The hazard 203 ratio (HR) along with the 95% CI were reported. A P value less than 0.05 was regarded as 204 statistically significant. All statistical analyses were performed using SPSS 25.0. Detailed 205 statistical analyses were shown in text andTable E6in the Online Repository.", "latex": null, "type": "table"}, "TABREF1": {"text": ". Compared with nonsevere 238 cases, severe cases exhibited more comorbidities, including chronic obstructive pulmonary disease 239 (4.8% vs. 1.4%, p=0.026), coronary heart disease (10.4% vs. 2.2%, p<0.001), hypertension (38.7% 240 vs. 22.2%, p<0.001), and diabetes (19.3% vs. 11.1%, p=0.009) respectively. Only five cases of 241", "latex": null, "type": "table"}, "TABREF2": {"text": ". All the above-mentioned complications were more common in 300 severe cases, compared with nonsevere cases (all P<0.05). Antiviral drugs were used specifically to treat COVID-19 during hospitalization, including 302 lopinavir/ritonavir (29.9%), umifenovir (73.2%), oseltamivir (40.3%), ribavirin (5.3%), and those in severe cases except for ribavirin. 341 (62.2%) of 548 patients were administered with systemic corticosteroids with a medium duration of 4 days and medium cumulative dose 306 equivalent to 200 mg prednisone. Of the 548 patients, 355 (64.8%) required oxygen support 307 Mortality rates for COVID-19 were estimated to be 1.1% (3 of 277) in nonsevere patients and 32.5% 310 (87 of 268) in severe cases during the average 32 days of follow-up. 72.9% of nonsevere cases and 311 31.7% of severe cases were discharged from hospital. 312 1.2-3.3) at admission, cardiac injury (adjusted HR 2.9; 95% CI 1.8-4.8), hyperglycemia (adjusted 317 HR 1.8; 95% CI 1.1-2.8), and administration of high-dose corticosteroids (adjusted HR 3.5; 95% 318", "latex": null, "type": "table"}, "TABREF3": {"text": "Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor World Health Organization. Summary of probable SARS cases with onset of illness of America. Am J Respir Crit Care Med 2019; 200:e45-e67. Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020. McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020. Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020. 10. He L, Ding Y, Zhang Q, Che X, He Y, Shen H, et al. Expression of elevated levels of 510 pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: relation to the acute lung injury and pathogenesis of SARS. J Pathol 2006; Chan MH, Wong CK. Severe acute respiratory syndrome: clinical and 514 laboratory manifestations. Clin Biochem Rev 2004; 25:121-32. 12. Sheng WH, Chiang BL, Chang SC, Ho HN, Wang JT, Chen YC, et al. Clinical manifestations and inflammatory cytokine responses in patients with severe acute 517 respiratory syndrome. J Formos Med Assoc 2005; 104:715-23. 13. Zhu M. SARS Immunity and Vaccination. Cell Mol Immunol 2004; 1:193-8. 14. Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, et al. Prevalence, risk factors, and converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 2005; Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature Shental O, Tchebiner JZ, Laufer-Perl M, Wasserman A, Sella T, et al. Diagnostic and prognostic value of very high serum lactate dehydrogenase in admitted medical patients. Isr Med Assoc J 2014; 16:439-43. Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for 553 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort 554 study. Lancet 2020; 395:1054-62.", "latex": null, "type": "table"}, "TABREF4": {"text": "OR=odds ratio. CI=confidence interval.Table 1. Epidemiological, demographic and clinical characteristics of hospitalized patients with available data. P values comparing nonsevere cases and severe cases are from \u03c7\u00b2 test, Fisher's exact test, a Days from December 1, 2019 to the date of onset.ACEI/ARB=angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.Table 2. Radiographic and laboratory findings of patients with COVID-19", "latex": null, "type": "table"}}, "back_matter": []}